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Influence of doxorubicin on model 
cell membrane properties: insights 
from in vitro and in silico studies
Ana Catarina Alves1, Aniket Magarkar2,3, Miguel Horta1, Jose L. F. C. Lima1, Alex Bunker3, 
Cláudia Nunes  1 & Salette Reis1
Despite doxorubicin being commonly used in chemotherapy there still remain significant holes in our 
knowledge regarding its delivery efficacy and an observed resistance mechanism that is postulated 
to involve the cell membrane. One possible mechanism is the efflux by protein P-gp, which is found 
predominantly in cholesterol enriched domains. Thereby, a hypothesis for the vulnerability of 
doxorubicin to efflux through P-gp is its enhanced affinity for the ordered cholesterol rich regions of 
the plasma membrane. Thus, we have studied doxorubicin’s interaction with model membranes in a 
cholesterol rich, ordered environment and in liquid-disordered cholesterol poor environment. We have 
combined three separate experimental protocols: UV-Vis spectrophotometry, fluorescence quenching 
and steady-state anisotropy and computational molecular dynamics modeling. Our results show that 
the presence of cholesterol induces a change in membrane structure and doesn’t impair doxorubicin’s 
membrane partitioning, but reduces drug’s influence on membrane fluidity without directly interacting 
with it. It is thus possible that the resistance mechanism that lowers the efficacy of doxorubicin, results 
from an increased density in membrane regions where the efflux proteins are present. This work 
represents a successful approach, combining experimental and computational studies of membrane 
based systems to unveil the behavior of drugs and candidate drug molecules.
Doxorubicin (as shown in Fig. 1) is one of the most widely prescribed anticancer drugs1. The most prevalent 
opinion is that the anticancer activity of the drug is mainly due to direct interaction with nucleic acids, leading 
to DNA damage and inhibition of DNA synthesis. This is, however, still the subject of considerable debate1; there 
is also strong evidence suggesting that interaction with cell membranes plays a role in its activity2. Clearly, even 
if the dominant mechanism is the interaction with the nucleic acids, doxorubicin must pass through a variety of 
other organelles to reach the DNA3. First, the drug must pass the selective barrier to entry into the cell that is the 
cell membrane and, finally, the nuclear membrane. Thereby, interaction with lipid membranes is an unavoidable 
step in doxorubicin activity, whatever the exact mechanism of action proves to be.
Drug-membrane interactions produce alterations in the physical properties of the cell membrane, as a result 
of the behavior of the drug within the membrane. How the drug orients in the membrane, which components 
of the lipid membrane the drug interacts with and what interactions within the membrane the drug disrupts, 
will all alter the physical properties of the membrane4. This can, in turn, lead to changes in cell signaling and the 
function of membrane proteins, e.g. transporters and ion channels5. It was, for example, found that Daunorubicin 
(a doxorubicin analog) causes alteration of both G-proteins and protein kinase C-associated signaling pathways, 
through destabilizing the non-lamellar membrane structures that are involved in their location and activity6, 7. As 
these proteins participate in fundamental functions of the cell, including proliferation and differentiation, their 
modulation could be responsible for the antitumor activity of some drugs6.
Within the membrane, the lipids are heterogeneously distributed into dynamic domains; domains enriched 
in cholesterol and sphingolipids are thought to form a highly ordered, liquid-ordered phase (lo), rafts that met-
aphorically float in a liquid-disordered phase (ld) matrix8. The function of several membrane proteins is highly 
dependent on their association with these domains9, 10. Among the proteins thought to be associated with lipid 
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rafts11 is P-glycoprotein (P-gp)12 that effluxes a variety of hydrophobic, neutral, and positively charged drugs from 
the cell. P-gp is a component of the normal cellular defense system against xenobiotics13. This protein has been 
shown to be highly sensitive to membrane fluidity; thus, any changes in membrane fluidity will alter the ability of 
P-gp to efflux drug molecules11.
Doxorubicin is among the substrates effluxed by P-gp; thus, in this case, this protein plays a key role in drug 
resistance14. What is not so well understood, however, is: 1) how doxorubicin partitions between the lo rafts 
and the ld matrix and 2) how doxorubicin alters the physical properties of the lipid rafts. This has considerable 
relevance regarding the behavior of doxorubicin as a drug. In fact, the manner in which doxorubicin partitions 
between the two phases of the plasma membrane will determine its susceptibility to P-gp: the greater the extent 
to which doxorubicin partitions to the P-gp rich rafts the greater its susceptibility to efflux. Additionally, the effect 
of the presence of doxorubicin on the structure of the lo raft can not only effect P-gp function, but also result in 
the modulation of the physicochemical properties of the membrane itself. This could, in turn, initiate different 
processes implicated in the anticancer cytotoxic effects of the drug. Several anticancer drugs, in fact, induce 
modifications in the content of lipid rafts, leading to growth inhibition and activation of tumor cells apoptosis9.
In light of all of this, we set out to apply a combined protocol of in vitro experimental analysis techniques, 
including UV-Vis spectrophotometry, fluorescence quenching and steady state anisotropy, both using membrane 
bound fluorescent probes and in silico computational modeling, to study the interaction of doxorubicin with the 
plasma membrane. Properties studied include: 1) effect of doxorubicin on membrane fluidity, 2) distribution 
of doxorubicin between the lo and ld phases and, 3) through computational molecular dynamics modeling, the 
microscopic details of the membrane-doxorubicin interactions. We show that cholesterol, present in the lo rafts 
but not so prevalent in the ld matrix, alters the behavior of doxorubicin in the membrane without directly inter-
acting with it. This interaction occurs in a fashion that promotes increased location of doxorubicin to the lo rafts, 
possibly increasing uptake by the P-gp efflux protein. We propose that this could possibly be a mechanism that 
contributes to the doxorubicin chemoresistance problem.
Results and Discussion
Doxorubicin Partition Coefficients. The partitioning of drugs into biological membranes plays a signif-
icant role in their uptake, transport, bioavailability and distribution15. In fact, doxorubicin needs to cross the 
cell membrane to reach its intracellular targets, for example DNA, and the interaction with lipids can strongly 
influence the pharmacokinetic and pharmacodynamic properties15 of the drug. The partition coefficient (Kp), 
is an important property to determine, as it provides information concerning the distribution of drugs between 
aqueous and lipid phases, of direct relevance to the pharmacological activity of the drug. The doxorubicin parti-
tion coefficient in several model membranes was determined through derivative UV-Vis spectrophotometry. This 
technique, based on the fact that the spectral characteristics (λmax) of the drug change when it permeates from the 
aqueous to the lipid medium, allows for the quantification of drug distribution between each phase. Furthermore, 
it also provides a better resolution of the overlapped bands and eliminates the lipid light scattering interference 
through the use of the derivative method.
Figure 2(A) shows, as an example, the third-derivative absorption spectra of doxorubicin with different con-
centrations of liposomes composed of DMPC:SM [8:2] at pH 7.4 and at 37 °C. The use of the third-derivative 
allowed the elimination of the residual background signal caused by scattering from the liposomes. The best fit of 
equation 1 to the third-derivative data was achieved at 544 nm and is shown in Fig. 2(B).
The experimental values obtained for the doxorubicin partition coefficient with DMPC:SM and 
DMPC:SM:Chol (expressed as Kp and logD) are depicted in Table 1.
Traditionally, the partition coefficient is assessed in octanol/water systems. The octanol/water logD of dox-
orubicin at pH 7.4, obtained using Marvin sketch calculator software (ChemAxon), was 0.02. Thereby, a lack of 
correlation between the doxorubicin partitioning coefficients obtained in liposome/buffer and octanol/water sys-
tems can be observed. Such difference is due to the fact that the biphasic octanol/water system can only account 
for hydrophobic interactions. Liposomes, on the other hand, provide an anisotropic environment that can better 
mimic membranes, which are composed by amphiphilic phospholipids and can, therefore, establish electrostatic 
Figure 1. Molecular structure and pKa value of doxorubicin.
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and hydrophobic interactions. In addition, the pKa value (9.93), calculated using Marvin sketch calculator soft-
ware, predict that nearly 80% of doxorubicin molecules are in the cationic form at pH 7.4, providing evidence 
that not only hydrophobic intermolecular forces drive the doxorubicin’s partitioning. In fact, the octanol/water 
partition coefficient value is much smaller than that calculated by the liposome/buffer system, since it only reflects 
the hydrophobic interactions of a small number of molecules that are in the neutral form at pH 7.4. Hence, the use 
of a liposomes/buffer system allows one to obtain more realistic information regarding doxorubicin lipophilicity 
and, therefore, it’s in vivo membrane partitioning.
Furthermore, the gathered experimental results reveal that doxorubicin exhibits a similar membrane parti-
tioning with both DMPC:SM and DMPC:SM:Chol liposomes. This suggests that the positively charged doxoru-
bicin interacts with the phospholipid polar head groups of both models and that the presence of Chol does not 
impair such partitioning.
Drug location studies using different fluorescent probes. The location of doxorubicin in the mem-
brane was tracked through fluorescence quenching of membrane bound probes (TMA-DPH and DPH), since this 
technique provides a measure of the accessibility of the drug to each probe16. Such knowledge is only possible to 
obtain due to the fact that the fluorophore position in the membrane is well defined and documented. Therefore, 
while DPH is deeply incorporated in the hydrophobic regions of the lipid bilayer17, TMA-DPH is reported to be 
anchored in the polar head groups region of phospholipids due to its charged group18. According to this, in the 
current study the steady-state fluorescence intensities and lifetimes were measured in liposomes labeled with 
TMA-DPH and DPH probes. The theory and equations behind this technique are presented in the supporting 
information.
In Fig. 3, the Stern-Volmer plots of I0/I−1 and τ0/τ−1 as a function of doxorubicin membrane concentration 
are shown, for the DMPC:SM [8:2] model.
According to the description of the quenching behavior (see supporting information), the quenching param-
eter values, namely the dynamic constant (KD), the static constant (KS) and the Stern–Volmer constant (KSV), 
obtained from this technique are depicted in Table 2.
From the analysis of Table 2, it is possible to conclude that the quenching process, in all mimetic model sys-
tems studied and probes used, results from both dynamic and static interactions. This behavior indicates that 
doxorubicin must diffuse into the fluorophore during the lifetime of the excited state; however, it can also form a 
non-fluorescent complex with the probe. According to the results, doxorubicin was able to quench both probes, 
DPH and TMA-DPH. Nevertheless, the KSV values demonstrate that the decrease of the DPH fluorescence was 
more pronounced than for TMA-DPH in the membrane model composed of DMPC:SM [8:2]. This suggests that 
doxorubicin interacts with the lipid head groups of the phospholipids, but the drug’s dihydroanthraquinone resi-
due may also interact with the lipid fatty acid chains through hydrophobic interactions. For the bilayer comprised 
by DMPC:SM:Chol [7:1.5:1.5] similar values of KSV were obtained for both fluorescent probes, which means 
Figure 2. Third-derivative absorption spectra (A) of doxorubicin (40 μM) (red line, 0) alone, incubated in 
DMPC:SM model membrane at 37 °C with increasing lipid concentration (7 represents the maximum lipid 
concentration) and the model membrane without drug (black lines). (B) represents the best fitting curve to 
experimental third-derivative spectrophotometric data (DT vs. [L]) using a nonlinear regression method at a 
wavelength of 544 nm.
Model Kp Experimental logD
DMPC:SM 8195 ± 406 3.91 ± 0.02
DMPC:SM:Chol 8707 ± 523 3.94 ± 0.03
Table 1. Partition Coefficients (expressed as Kp and logD) of doxorubicin in DMPC:SM [8:2] and 
DMPC:SM:Chol [7:1.5:1.5] at pH 7.4 and 37 °Ca. aAll values represent the mean ± standard deviation (n = 3). 
*p < 0.05 statistically different from the other model.
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that doxorubicin has an identical accessibility to DPH and TMA-DPH in the model membranes with cholesterol 
present.
Effect of Doxorubicin in membrane fluidity. Since doxorubicin interacts with membranes in order to 
exert its therapeutic action, it is important to understand how the compound can influence the physicochemi-
cal state of the phospholipid bilayer in order to explain its pharmacological action. Furthermore, alterations of 
membrane fluidity can severely affect the cell’s functional properties that might be correlated with the drug’s 
mechanism of action. In this context, membrane fluidity studies were performed by steady-state anisotropy19 
using fluorescent probes (DPH and TMA-DPH). The ability of doxorubicin to disturb the membrane structure in 
different regions can be assessed since these two probes report the microfluidity of those sites20. Modifications in 
membrane fluidity can be detected by changes in anisotropy, which reflects perturbations in the probe’s rotational 
movement caused by the changes in the stiffness of its surrounding matrix21.
The effect of temperature on the DPH and TMA-DPH fluorescence anisotropy of the different model mem-
branes without doxorubicin is presented in Fig. 4. The results demonstrate that the anisotropy values in both 
model membranes decrease with increasing temperature to a greater extent in the acyl chain region (given by the 
probe DPH) than in the phospholipid head region (given by the TMA-DPH probe). In fact, it is well documented 
that the membrane is characterized by a fluidity gradient from the aqueous interface to the bilayer interior, where 
the acyl chain end shows increased disorder. Also, it is known that the presence of SM and Chol in membranes 
promotes the formation and maintenance of specific domains in the liquid-ordered phase, more condensed and 
organized22, which results in higher anisotropy values.
Figure 5 shows the influence of doxorubicin on the DPH and TMA-DPH fluorescence anisotropy as a function 
of temperature for each model system studied. Regarding the model membrane composed of DMPC:SM two 
distinct doxorubicin behaviors can be observed in the different regions of the membrane. Namely, doxorubicin 
increased the membrane fluidity of the phospholipid’s acyl chains, in a more ordered phase of the bilayer, and 
decreased the membrane microviscosity, in a more fluid phase of the bilayer. This represents a similar behavior as 
Chol possesses when in incorporated in the membrane, helping to prevent the membrane from becoming either 
too fluid or too rigid, due to the ability of cholesterol to cause disordering of gel-phase lipids while still maintain-
ing a high degree of orientational ordering. At the same time, DOX decreased the membrane microviscosity in 
the phospholipid’s head groups. These findings are, once again, consistent with the previous results of partition 
and location, where it has been observed that the anticancer drug establishes electrostatic interactions and hydro-
gen bonds with the negative phosphate group and hydrophobic interactions with the hydrocarbon chains of the 
phospholipids.
Figure 3. Stern–Volmer plots of the probe DPH in DMPC:SM [8:2] model at pH 7.4 and 37 °C with increasing 
doxorubicin concentrations: square symbols (◾) represent the Stern–Volmer plot obtained by steady-state 
fluorescence measurements (I0/I−1) and circle symbols ( ) represent the Stern–Volmer plot obtained by 
lifetime fluorescence measurements (τ0/τ−1).
Model Probe KD (M−1) KS (M−1) KSV (M−1)
DMPC:SM
DPH 7.4* ± 0.2 6.4 ± 0.3 13.8* ± 0.4
TMA-DPH 6* ± 1 6.0 ± 0.3 11* ± 1
DMPC:SM:Chol
DPH 3.2* ± 0.4 3.2* ± 0.2 6.4 ± 0.2
TMA-DPH 2.5* ± 0.2 4.2* ± 0.2 6.6 ± 0.1
Table 2. Fluorescence quenching parameters (KD, dynamic constant; KS, static constant; KSV, Stern–Volmer 
constant) determined from the quenching of DPH and TMA-DPH by doxorubicin in the different mimetic 
models at pH 7.4 and 37 °Ca. aAll values represent the mean ± standard deviation (n = 3). *p < 0.05 statistically 
different from the other probe, for each fluorescence quenching parameter.
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On the other hand, it can be observed that doxorubicin did not produced any alterations in the membrane 
fluidity of DMPC:SM:Chol model along the bilayer. This fact can be correlated with the disposition of the mol-
ecules within the phospholipid membrane. Doxorubicin is a molecule that possesses an aromatic ring wherein 
its planar structure bears resemblance to the structure of cholesterol. According to the location studies, doxoru-
bicin has an identical accessibility to both DPH and TMA-DPH probes. Considering that the presence of Chol 
reduces the membrane fluidity, it is possible that doxorubicin does not cause significant alteration in the overall 
fluidity in both superficial and deeper regions of phospholipids. Furthermore, due to interactions between NH3+ 
Figure 4. Steady-state anisotropy of DPH and TMA-DPH as a function of temperature in DMPC:SM [8:2] and 
DMPC:SM:Chol [7:1.5:1.5] membrane models. Results present the mean of at least three independent assays.
Figure 5. Steady-state anisotropy of DPH and TMA-DPH as a function of temperature in each mimetic model, 
in the absence (◾), and in the presence of doxorubicin 40 µM ( ) and 75 µM ( ). Results present the mean of at 
least three independent assays.
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of doxorubicin and the phosphate group in the polar head of the phospholipids, the further access of doxorubicin 
into the membrane might be impaired.
The presence of SM together with Chol form within the membrane, liquid-ordered domains that are charac-
terized by a low density and rigid environment, as shown through anisotropy measurements. It has been demon-
strated by several structure–activity studies that hydrophobicity and the presence of planar aromatic regions, as 
in the case of doxorubicin, favor the drug-P-gp interaction23. Furthermore, it was also reported that increase of 
membrane fluidity can lead to an inhibition of P-gp function24. Since our results demonstrate that doxorubicin 
did not cause any changes in the fluidity of the DMPC:SM:Chol model membrane and that the drug’s binding 
sites on the P-gp are via the lipid membrane25, it is possible to correlate the gathered outcomes with the resistance 
problem associated with doxorubicin administration.
Molecular Dynamics simulation results: Interaction of doxorubicin with membrane bilayers. 
We used MD simulation with all atom resolution to study the partitioning of doxorubicin into the DMPC:SM 
and DMPC:SM:Chol membrane bilayers. In all simulations, doxorubicin molecules were placed in the solvent 
at least 1.5 nm away from the lipid headgroups. The z-coordinate of the center of mass of doxorubicin molecule 
and z-coordinate of the center of mass of phosphate group vs time is shown in Fig. 6A and B. This analysis shows 
that the doxorubicin molecule partitions closer to the lipid-water interface in the presence of cholesterol, in good 
agreement with the derivative spectrophotometry studies. Furthermore, the angle of distribution of the doxo-
rubicin molecule with the membrane normal (shown in red in Fig. 6C) shows that the orientation of the anti-
cancer drug in the presence of cholesterol is significantly altered. As seen in Figs 6C and S2A, in the DMPC:SM 
membrane bilayer, the doxorubicin cyclic group (dihydroanthraquinone residue) is perpendicular to the mem-
brane normal; however for the DMPC:SM:Chol membrane, the presence of cholesterol increases the degree of 
membrane ordering, resulting in an orientation change such that the average angle of doxorubicin to the mem-
brane normal becomes 22 degrees. Such a difference in the doxorubicin orientation, concerning the two model 
membranes, might help to explain why alterations in membrane fluidity are more pronounced in the DMPC:SM 
bilayer. Furthermore, the increase in membrane ordering that results from the presence of cholesterol is traduced 
by an increase in membrane thickness, as shown in the Figure S2B. Also, the addition of cholesterol decreases the 
number of non-bonded contacts of lipids and cholesterol with doxorubicin as shown in Figure S3. However, in 
the presence of cholesterol, the number of hydrogen bonds between doxorubicin and both the lipids and choles-
terol increases, as presented in Figure S4A and B. Also in Figure S4, we display the specific groups of doxorubicin 
involved in hydrogen bonding with lipids and both cholesterol (A) and water (B).
The high partitioning of doxorubicin with the two models can be explained by its ability to interact with the 
lipid tails as demonstrated in Figure S3 and to form hydrogen bonds with lipid headgroups (Figure S4).
In the previous simulation studies by Yacoub et al.26 it was demonstrated that the doxorubicin molecule has 
a significant effect on lipid ordering in the DPPC membrane bilayer. In this light, to investigate the effect of the 
insertion of a single doxorubicin molecule into the model membranes chosen for this study, we calculated the 
deuterium order parameter for the sn-2 chain of the DMPC molecule in both presence and absence of the dox-
orubicin molecule. The deuterium order parameter, SCD27, is a property of the bilayer that provides information 
concerning the level of lipid chain ordering. It can be obtained accurately from NMR experiments and is defined 
as follows:
= θ −S (3/2cos 1/2) (1)CD
2
i
where θi is the angle between the C–D bond (C–H in simulations) of the i carbon atom and the bilayer normal. 
The angular brackets denote averaging over time and over relevant C–D bonds in the bilayer.
As shown in Fig. 7, we see that the change in the deuterium order parameter and thus, the degree of lipid chain 
ordering, that results from the presence of the doxorubicin molecule, is more pronounced for the DMPC:SM 
membrane than for the DMPC:SM:Chol membrane. This observation is in agreement with the fluidity measure-
ments obtained from fluorescence anisotropy, as shown in Fig. 5.
We thus observed that, as a result of the presence of cholesterol: 1) the orientation of the doxorubicin mole-
cule in the membrane bilayer is altered, 2) the number hydrogen bonds between Doxorubicin and the membrane 
lipids is increased and 3) the extent of non-bonded interactions is decreased (Figure S3). In spite of this marked 
effect, the extent of direct interaction between cholesterol and doxorubicin was found to be relatively insignifi-
cant, as seen in Fig. 8. This might be explained by the fact that the OH group of cholesterol is masked by the polar 
head of the sphingomyelin in a typical “umbrella” effect28 and, thus, not available to interact with the doxorubicin 
molecule. In Fig. 8 the distribution of the measured distances between doxorubicin and DMPC, SM and Chol 
is shown. From this plot, it is clear that doxorubicin preferentially locates in close proximity to both the SM and 
DMPC molecules in the membrane. Hence the effect of cholesterol on the behavior of the membrane is significant 
even though this effect is not the result of direct interaction, but rather the change in the membrane structure that 
results from the presence of cholesterol.
Conclusion
The present work investigated the molecular interactions and the behavior of an extensively used drug, dox-
orubicin, with model membranes composed of DMPC and SM, both in the presence (ordered) and absence 
(liquid-disordered) of Chol using combined in vitro and in silico models. Our goal was to shed light on the dif-
ference in behavior of doxorubicin in cholesterol rich ordered rafts from the rest of the biomembrane. The inter-
action of doxorubicin with a lipid membrane, i.e. how it positions in the membrane, was found to be strongly 
affected by the ordering effect of cholesterol. In all cases doxorubicin located within our model membranes, 
driven by non-bonded interactions (electrostatic, hydrophobic and Van der Waals interactions), as observed by 
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both in vitro and in silico results. Furthermore, in the presence of cholesterol, the doxorubicin 1) preferentially 
partitions within the bilayer closer to the lipid-water interface and 2) displays an increased number of hydrogen 
bonds with both lipid and water molecules. Cholesterol is present in plasma membranes and modulates its phys-
ical properties. Any change produced as a result of drug-cholesterol interactions in modulating the function of 
cholesterol is of particular importance; this has been studied extensively in recent years29. In our studies, how-
ever, cholesterol was found to not interact directly with the drug and the effect of the presence of cholesterol was 
solely due to its the ordering effect in membrane structure. Collectively the in vitro and in silico results combine 
to build this picture, where it was possible to demonstrate that the presence of cholesterol does not reduce dox-
orubicin membrane partitioning, but it influences the drug’s ability to alter membrane fluidity. Furthermore, 
computational results show that cholesterol alters the behavior of the doxorubicin in the membrane without 
Figure 6. Partitioning of doxorubicin into the membrane bilayer models. The plot shows z-coordinate vs 
time for the center of mass of the phosphate group (of DMPC and SM) and doxorubicin molecules for (A) 
DMPC:SM [8:2] and (B) DMPC:SM:Chol [7:1.5:1.5] membranes. The red dotted line represents time point 
where systems were considered to be equilibrated, and for all analysis trajectory past this point (200 ns) 
was used. (C) The Angle distribution of doxorubicin in with membrane normal, in DMPC:SM (blue) and 
DMPC:SM:Chol (red) membranes. The error values represented are calculated as block errors.
www.nature.com/scientificreports/
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itself interacting with the doxorubicin: the effect is mediated through how it alters the membrane structure. This 
result can shed light on the doxorubicin chemoresistance problem as follows: 1) P-gp, the protein responsible 
for removal of xenobiotics like doxorubicin, preferential locates to lipid rafts and 2) our results now indicate that 
doxorubicin also preferentially locates to lipid rafts rich in cholesterol11, thus increasing their bioavailability to the 
efflux pump probably responsible for the reduced drug concentration inside the cell.
Materials and Methods
In this work, we have studied synthetic models (liposomes) composed of 1,2-dimyristoyl-sn-glycero-3-p
hosphocholine (DMPC), sphingomyelin (SM) and cholesterol (Chol) were used in order to mimic specific mem-
brane characteristics such as the presence of lipid rafts. Phosphatidylcholines are among the most abundant 
phospholipids of natural plasma membranes4 and were, for that reason, included in the mimetic models as the 
dominant constituent (DMPC). Sphingomyelin and cholesterol are important components of the cell membrane 
that undergo tight packing with phosphatidylcholines, forming the so called dynamic lipid rafts/nano-domains. 
These structures also control membrane fluidity and permeability, crucial for the preservation of its organization 
and, consequently, contributing to the cell membrane’s physiology and function30. Thereby, the ability of doxo-
rubicin to partitioning into lipid bilayers (assessed by calculating the coefficient partition, Kp, using derivative 
spectrophotometry), its location within the membrane (by fluorescence quenching) and its effect in the mem-
brane fluidity (through fluorescence anisotropy) were investigated. Molecular simulations were also performed, 
using the same lipid composition, in order to gain further insight regarding the interactions of doxorubicin with 
the studied model membranes.
Reagents. Doxorubicin (DOX) was obtained from LC Laboratories (Woburn, Massachusetts, USA). The 
lipids 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), sphingomyelin (SM) and cholesterol (Chol) 
were supplied by Avanti Polar Lipids, Inc. (Alabama, USA). The probes 1,6-diphenyl-1,3,5-hexatriene (DPH) 
and 1-(4-trimethylammoniophenyl)-6-phenyl-1,3,5-hexatriene (TMA-DPH) were purchased from Molecular 
Figure 7. Order parameter of the sn-2 chain of DMPC molecule. Order parameter shows that the increase 
in lipid order parameter in DMPC:SM membrane is more pronounced as compared to DMPC:SM:Chol 
membrane in presence of doxorubicin molecule.
Figure 8. Molecular interactions of doxorubicin with individual components of the membrane bilayers: 
Radial distribution function of the DMPC, SM headgroups and cholesterol OH group from doxorubicin. (A) 
DMPC:SM [8:2] with doxorubicin and (B) DMPC:SM:Chol [7:1.5:1.5] with doxorubicin.
www.nature.com/scientificreports/
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Probes (Invitrogen Corporation, Carlsbad, California, USA). All reagents were used without further purification. 
Drug solutions were prepared with Hepes buffer (10 mM, pH 7.4) and the ionic strength was adjusted with NaCl 
(I = 0.1 M) to mimic physiological conditions. The buffer was prepared using double-deionized water (conduc-
tivity less than 0.1 μS cm−1).
Liposomes Preparation. Liposomes were prepared according to the adapted classic thin film hydration 
method31. Briefly, the lipids DMPC:SM [8:2] and DMPC:SM:Chol [7:1.5:1.5] were dissolved in chloroform/meth-
anol (3:2 v/v) and the organic solvents were evaporated under a stream of nitrogen in a rotative evaporator (Buchi 
R-200, equipped with a thermostated bath Buchi R-490, Switzerland). The obtained dried lipid film was dispersed 
in Hepes (pH 7.4) and the mixture was vortexed to yield multilamellar vesicles (MLVs). Large unilamellar vesi-
cles (LUVs) were obtained by extruding the MLVs eleven times (extruder supplied by Lipex Biomembranes Inc., 
Vancouver, Canada) using policarbonate filters with a diameter pore of 100 nm (Nucleopore) at 60 °C (temper-
ature above the main phase transition temperature of the lipids). Labeled liposomes were identically prepared, 
except that the fluorescence probe (DPH or TMA-DPH) was co-dissolved with lipids in the organic solvents 
mixture to give a probe/lipid molar ratio of 1:300 (prevent changes in the membrane’s structure).
Determination of Partition Coefficients by Derivative Spectrophotometry. Partition coeffi-
cient (Kp) of doxorubicin between liposomes/buffer systems was assessed by derivative spectrophotometry, as 
described in previous works21, 31, 32. For these studies, a set of samples containing a fixed concentration of doxo-
rubicin (40 μM) and increasing concentrations of lipids (in the range of 0–1250 μM) were prepared. The equiv-
alent references were identically prepared but without the drug. All suspensions were incubated during 30 min 
at 37 °C. The absorption spectra of all solutions were recorded at 37 °C using a multidetection microplate reader 
(Synergy™ HT, BioTek Instruments Inc, Winooski, VT, USA). The Kp values were calculated from the third 
derivative spectra using a developed routine, the Kp Calculator33, by fitting equation 1 to the experimental data 
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where, DT is the third derivative intensity (D = dnAbs/dλn) obtained from the absorbance values of the total 
amount of doxorubicin (DT), Dm and Dw, the doxorubicin distributed in the lipid membrane phase and in the 
aqueous phase respectively. [L] represents the lipid concentration (in M) and Vm is the lipid molar volume, cal-
culated from the weighted molecular mean and the reported volume of lipids, for the biomimetic membranes 
(DMPC:SM and DMPC:SM:Chol) were 0.682 and 0.633 L.mol−1, respectively. The Kp values obtained are dimen-
sionless and presented as the mean ± standard deviation calculated from at least three independent assays.
Drug Location Studies Evaluated by Fluorescence Quenching. Doxorubicin location within the 
model systems was assessed by fluorescence studies that included steady-state and time-resolved measure-
ments, according to an already described protocol34. These experiments were conducted by incubation of the 
anticancer-drug with DPH and TMA-DPH labeled liposomes. The samples containing a fixed concentration of 
lipid (500 μM) and increasing concentrations of doxorubicin (0, 40 and 75 μM), were incubated at 37 °C during 
30 min in the dark. The fluorescence measurements were carried out at 37 °C, at the excitation and emission 
wavelengths defined as 357 nm and 429 nm, and 359 nm and 429 nm, for DPH and TMA-DPH, respectively. 
Fluorescence steady-state measurements were performed in a Jasco FP-6500 spectrofluorometer (Jasco, Great 
Dunmow, UK) equipped with a constant temperature cell holder and all data were recorded in a 1 cm path length 
cuvette. For each measurement, the fluorescence emission was automatically acquired during 30 s. The fluores-
cence intensity values obtained were corrected for inner filter effects (quencher absorbance) at the excitation 
wavelength35. The fluorescence time-resolved measurements were performed using a Fluorolog Tau-3 Lifetime 
system. The modulation frequencies were acquired between 10 and 200 MHz, with an integration time of 10 s. The 
fluorescence emission was detected with a 90° scattering geometry. All measurements were made using Ludox as 
a reference standard (τ = 0.00 ns).
Membrane Fluidity Studies Evaluated by Fluorescence Anisotropy. The doxorubicin’s effect on 
the membrane microviscosity, in the different model membranes, was assessed by fluorescence anisotropy stud-
ies. Samples were prepared with a fixed concentration of lipid (500 μM), labeled with DPH or TMA-DPH, and 
increasing concentrations of doxorubicin (0, 40 and 75 μM), and incubated during 30 min at 37 °C in the dark. 
The steady-state fluorescence anisotropy values (rs) were recorded between 10 and 60 °C with intervals of 2 °C. 
The experiments were performed in a Jasco FP-6500 spectrofluorometer with polarizers inserted (excitation/
emission wavelengths were set as described for each fluorescent probe). The results obtained are presented as the 
mean ± standard deviation calculated from at least three independent assays.
Molecular Dynamics (MD) simulations. All-atom molecular dynamics simulations of doxorubicin 
molecule were performed with 2 membrane bilayers, with the following lipid compositions, DMPC:SM [8:2] 
DMPC:SM:Chol [7:1.5:1.5]. For lipid molecules S-lipids forcefield parameters were used36–38. For water mol-
ecules we used the TIP3P model compatible with the S-lipids forcefield set. Periodic boundary conditions 
with minimum image convention were used in all directions. Covalent bond lengths were preserved through 
the linear constraint solver (LINCS) algorithm39. For all systems the temperature was controlled using the 
Nosé-Hoover thermostat with solvent and solute controlled independently40, 41. Pressure was controlled using 
the Parrinello-Rahmann barostat with semi-isotropic control42. Lennard-Jones interactions were cut off at 1.4 nm 
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and for the electrostatic interactions the particle mesh Ewald method (PME)43 was used. For all simulations 
physiological pressure and temperature were used (1 Bar and 37 °C). The GROMACS open source software pack-
age, version 4.6.5, was used44 for all Molecular Dynamics (MD) simulations, along with all quantitative analysis. 
Visualization of the trajectories was performed using the Visual Molecular Dynamics (VMD) package45. For 
doxorubicin, the partial charges were derived with RESP46 procedure implemented in ANTECHAMBER47. All 
the simulation systems were simulated for 1.2 microsecond. The first 200 ns were considered as an equilibration 
phase and, hence all the analysis was performed on the latter 1 microsecond trajectories.
Statistical analysis. Statistical analysis was performed using IBM® SPSS® Statistics software (v.20.0.0.0, 
IBM, Armonk, NY, USA). The measurements were repeated at least three times and data was expressed as 
mean ± standard deviation (SD). Data was statistically analyzed through the one-way analysis of variance 
(ANOVA) method and differences between groups were compared by Bonferroni and Tukey post-hoc tests in 
which a p value lower than 0.05 (p < 0.05) was considered statistically significant.
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